We would love to hear your thoughts about our site and services, please take our survey here.
maj is sad very true. maybe desperate too? weeing his pants just a little bit? 😄 why do these cynical, mean ****d shorters think that they know better than the us? every time the nasdaq opens they keep buying. we're just giving them the opportunity to buy low. they're stocking up like some of us because they know that getting national medicare coverage for the whole of the us is big and there's a commitment there to reduce chronic kidney disease and eliminate serious kidney disease. it will save the us economy about £35 billion because that's what serious kidney disease costs. and it will save lives and increase productive and happy lives because serious kidney disease involves dialysis if you can't get a donor.
the authorities overseeing this consultation have pretty much recommended it. will post the morning star coverage later with the story on this. gla
Morning everyone,
I am wondering when the IM decision is due too. Any idea Stokey? Thx.
There's at least 19 that could be called 'large' ie. over £1 billion revenue. But not many that have an interest in renal disease or diagnostics. I suppose they're always looking at solid opportunities and some will be prepared to diversify their portfolio. They tend to prefer a focus on their core competencies though don't they?
Those of us who have expressed a view think AstraZeneca are the most likely to be the 'large strategic diagnostics company '.
Thermo Fischer have quite a significant focus on more severe kidney disease. I wonder if they might throw their hat in the ring too?
He's admitted he's shorting Sharebel. Wouldn't be surprised if he's on the books for Armistice.
Tomorrow is International Kidney Day. AZN sponsor it. Hope they say something.
Armistice started to reduce their short last month. I guess that's why the shorts are getting so desperate. Reckon they took it out mid 30s. Must be very uncomfortable for them.
I know Maj likes to give us the updates but only when we're down it seems 😆 I'm calling it a day for today. Will check in tomorrow. Gla.
😄 fair cop Maj, I didn't read the notice fully- someone here had said it was a good buy. V slack on my part. They're a hedge fund. Opportunistic. Their site said they had opened the position not closed it.
But they only have a couple of small health buys anyway. Not their main focus.
Pentwater aren't buying them. They've got a credible portfolio. Seem to be doing sensible things. Got more in us than they have in Amazon and Alphabet. Closed on Apple which is said to be overvalued atm. In a lot of tech, in JP Morgan, a few pharma and commercial property.
Reckon they know which way the wind is blowing. They're based in the US.
Yes. 3.4%. Got $6.5 billion worth of investments. Looks like they will have some US connections. We should try to find out more.
I will keep sharing reminders of why I'm invested but it's really easy to find out what the stakes are here.
The Morning Star has good coverage from 9th Feb 2024 when the US federal authorities for Medicare coverage (covering the whole of the US health insurance) said that they think it is 'reasonable and necessary ' to adopt Renaltix's Kidneyintel AI test for the 10-14 million Americans with diabetes 2 and early stage chronic kidney disease. It sounds over the top when it is priced at $950 for them to subsidise this at scale. About $9.5 billion if everyone who would benefit took the test. But they spend $85 billion on chronic kidney disease treatment and $35 billion on severe kidney disease treatment. The latter can be prevented if it's found early enough. Severe kidney disease is the 3rd highest reason for early mortality. So those are the stakes. A life saving test and treatment plan for a growing disease worldwide. The US are leading the way on this. Medicare coverage across the US would have transformed this company but it will instead contribute to the growth of another big pharma company. I suspect AstraZeneca are the bidders as do a lot of investors. Because they have an established relationship with RENX and have used the product in their partnership approach towards aiming to reduce high level and chronic kidney disease.
Why are you here then? We don't want to be in Bloe or we would be.
Flogit, the nomad is also a broker.
AstraZeneca paid £1.3 billion for the last small pharma that they bought.
Markets aren't open there. It's just tracking us.
Not sure I go along with the rampers on here. We're being hit by shorters and uncertainty now. I am holding because I have researched AstraZeneca and their work on kidney disease. They sponsor world kidney day which is coming up this week. They're committed to screening and testing 35 million people for kidney disease. They're constantly investing in treatment for both chronic and high kidney disease. But they're most committed to prevention. They buy out companies all the time. Analysts are saying they need to put more money into the pipeline to maintain their profits. They've partnered Renx for years and now Renx are about to get US insurance coverage for the whole of the US. The consultation process for this ends at the end of March. The US government has given them a contract for all of their armed services- army, navy and airforce. Small contribution to the finances but massive for credibility. They have FDA approval. This is the final hurdle. End of March is the timeline I am looking at for movement in the sp. In the meantime the likes of Investec will be in and out like yo yos causing an unstable sp. Whatever. The US keep buying because they can see the opportunity here. Our markets are an embarrassment. But AZN or another big player can reveal their intentions at any time at this point. Hedgies don't want retail to win. They resent us because we haven't paid into their funds.
And shorters and trolls will make hay while they can.
Think we'll get £2.00.
The US are going to be hacked off with our hedge funds. Yesterday you get Unicorn buying in and today you get Investec saying they were buying and selling for a 1p profit. It's to keep the price low so they can buy in cheaper. I am so fed up with their behaviour over the years. Aim needs to be regulated. I'm holding. they aren't scaring me out of good money. This is a life saving partnership on the table. It took RENX 3 years to get to this stage- FDA approval and now on the cusp of getting US Medicare right across the US. 10-13 million US citizens at high risk of kidney diseases or related kidney diseases. A way forward with early intervention and the right treatment to prevent escalation is there within a RENX and AZN partnership. We'll find out soon enough if it's AZN. They'd be getting a bargain at £2.00 if it is them. But what's to stop the likes of Gilead Science piling in? All to play for.
So we know that the collaboration was set up in August 2020. Here is another indication of the commitment continuing.
https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2021/from-diagnosis-to-late-stage-astrazenecas-commitment-to-patients-with-chronic-kidney-disease-11052021.html#
AZN want to eventually eliminate HKD, Renaltix's AI platform is a key part of their strategy. Read all about it on this link.
These silly games with the hedgies will continue for a couple of days until they tell us who has bid. Hold or buy. When the news is out if it goes our way this will be over but you won't get in at a sensible price. It will probably move close to the bid price and stay there unless the market expects a tussle for it from more than one big pharma.
Assume we'll get a leak soon enough about who the bidder is.
I suspect it fell because the US market woke to a significant increase from Friday cop. They've taken profits and will now buy back. The share is volatile because the company needs funds but they're also concluding the consultation for national health insurance coverage in the US. The market is a massive 10 million people- those with diabetes 2 who have health insurance? At $950 that's worth the interest of any big pharma.
Https://www.nsmedicaldevices.com/news/renalytixai-astrazeneca-ckd/
Looks like you'll have to cut and paste the link. Sorry for that.
The RENX platform has come on a lot since then and is now targeting those with diabetes 2 to establish any kidney disease at an early stage, not just those with established chronic kidney disease. The company says the market is potentially 10 million US citizens.
Maybe someone on stocktwits could post the link there too. They seem to be operating without this information.